Background: Approximately one third of the hereditary diffuse gastric cancer (HDGC) families carry germline mutations in the E-cadherin gene (CDH1). Risk prediction in members of families with this rare but deadly cancer could be improved by the identification of additional HDGC genes in non-CDH1 families.
Introduction
Gastric cancer can be divided histopathologically into intestinal and diffuse types. While intestinal type gastric cancer is more common, diffuse type gastric cancer is more likely to have a genetic basis. Hereditary diffuse gastric cancer (HDGC) is an autosomal dominant familial cancer in which 46% of the patients show CDH1 germline mutations or deletions (1) . CDH1 mutations are thought to account for 1% of all gastric cancer cases overall (2) . Because half of the HDGC families are negative for E-cadherin germline mutations, the identification of additional genes underlying this familial cancer is important.
E-cadherin is a transmembrane protein encoded by CDH1 that functions in the differentiation and polarization of the gastric epithelium through binding to identical molecules on adjacent cell surfaces. Proper function of Ecadherin requires its anchoring to the cytoskeleton by the 4 members of the catenin family [reviewed by Tian and colleagues (3)]. Inactivation of catenins and disruption of cytoplasmic catenin-cadherin binding result in inability of E-cadherin to establish cell-to-cell adhesion even when the extracellular E-cadherin binding domain remains intact. CTNNA1 encodes a-catenin, which binds actin binding proteins and filaments. The cytoplasmic tail of a-catenin can be bound by either b-catenin (encoded by CTNNB1) or g-catenin (plakoglobin), the product of JUP. CTNND1 encodes p120-catenin, a multi-isoform protein expressed differentially in a variety of cell types. p120 interacts with the juxtamembrane domain of E-cadherin and regulates the lateral clustering and stabilization of the cadherins at the cell membrane. Abnormal expression of both the E-cadherin and catenin genes has previously been shown in diffuse gastric cancer. Given the importance of catenins in regulating E-cadherin function, we hypothesized that screening of these genes in HDGC families without CDH1 mutations would identify potential new germline mutations responsible for HDGC.
Materials and Methods

Patients and families
Twenty-two families from Canada, the United States, and the United Kingdom were screened. These families, including their characteristics and criteria for ascertainment and testing were part of a larger set described previously (4) . Families numbered 3, 5-6, 8, 12, 14, 15, 17, 19, 22-24, 27, 28, 30-35, 37, and 38 were previously confirmed as without CDH1 mutations (4) and thus included in this study. Constitutional genomic DNA was extracted from blood from at least 1 affected individual of each family, usually the proband. This study was approved by the joint British Columbia Cancer Agency/ University of British Columbia (BCCA/UBC) Clinical Research Ethics Board. Informed consent was obtained for all participants.
Resequencing
The sequencing methodology used was described previously (4). Amplicons were designed to allow assessment of each entire coding exon including intron-exon junctions. Seventeen exons of CTNNA1, 15 exons of CTNNB1, 13 exons of JUP, and 19 exons of CTNND1 were screened. Primers and PCR conditions are given in Supplementary Online Material. Bidirectional sequence data were obtained on ABI-3700 sequencers then assembled and viewed in Polyphred/Consed. The programs SIFT ("Sorting Intolerant from Tolerant") (5) and Polyphen-2 (6) were used to assess the potential functional impact of variants.
Results
The 22 families were screened for mutations in the 4 catenin genes. Variants observed are listed in Table 1 . Four synonymous variants were found in CTNNA1, 2 in CTNNB1, 8 in JUP, and 3 in CTNND1. Only JUP contained nonsynonymous variants: a conservative substitution (Val322Met) and 2 that were predicted to be "possibly damaging" by Polyphen, Arg144His, and Arg178Trp, with the latter indicated as "not tolerated" by SIFT.
Discussion
The only mutations with possible functional significance were found in JUP. Both of these were heterozygous and rare (observed in only 1/50 chromosomes). Because plakoglobin and b-catenin have overlapping roles in binding a-catenin, and no mutations were found in CTNNB1, it is unlikely that the rare mutations found in the JUP gene would have severe functional consequences. Catenin genes have been screened in gastric cancer tumor tissue previously with little evidence for a strong role of catenin mutations in gastric tumorigenesis. To our knowledge, our study is the first to screen these genes in HDGC families.
Because the kinase-driven pathways of the cadherincatenin complex are critical to its structural integrity (7) and a-actin may act in the regulation of the cytoskeletal organization (8) , it is possible that changes in the regulatory pathways of the cadherin-catenin complex could play a larger role than mutations within the catenin genes. It seems likely that genetic variation in catenin genes themselves has little if any effect on HDGC risk.
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